Ownership and insider activity for Ensysce Biosciences, Inc. (ENSC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.
Price
| Price | $0.45 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-07 | GOWER BOB G | P-Purchase | 400,000 | $198K |
| 2026-04-23 | GOWER BOB G | P-Purchase | 508,614 | $246K |
| 2026-04-23 | GOWER BOB G | C-Conversion | 254,307 | $123K |
| 2026-08-05 | Morrison James William | 154,821,000 | ||
| 2023-03-02 | GOWER BOB G | P-Purchase | 90,287 | $44K |
| 2023-03-01 | GOWER BOB G | P-Purchase | 270,000 | $129K |
| 2023-02-28 | GOWER BOB G | P-Purchase | 109,300 | $53K |
| 2022-12-09 | GOWER BOB G | P-Purchase | 357,143 | $500K |
| 2022-12-09 | GOWER BOB G | A-Award | 714,286 | $1.0M |
| 2022-06-23 | Chang William H | A-Award | 15,000 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $1.7M | $341536 | $194214 | $12.3M | $3.1M | $1.1M | $3.5M | $4.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $170535 | $173552 | 0 | $441721 | $276821 | $97561 | $124115 | $420345 |
| Inventory | 0 | 0 | 0 | 0 | -$441721 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.3M | $1.9M | $618590 | $347876 | $15.7M | $5.3M | $2.3M | $5.3M | $7.2M |
| Property, Plant & Equipment | 0 | 0 | $351 | $151 | $24.72B | 0 | 0 | 0 | $124129 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $202.4M | $204.8M | $623941 | $351807 | $16.4M | $5.9M | $2.7M | $5.6M | $7.5M |
| Accounts Payable | 0 | 0 | $540778 | $1.7M | $301104 | $2.9M | $1.9M | $1.4M | $3.3M |
| Short-term Debt | 0 | 0 | $2.6M | $4.2M | $12.7M | $4.3M | $854697 | $301660 | $306708 |
| Total Current Liabilities | $156239 | $437886 | $7.3M | $7.0M | $16.5M | $9.5M | $3.3M | $2.2M | $4.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | $4.4M | $140148 | 0 | 0 | 0 |
| Total Liabilities | $7.2M | $7.4M | $7.3M | $7.0M | $24.6M | $9.9M | $3.4M | $2.2M | $4.6M |
| Retained Earnings | -$31193 | $2.1M | -$56.0M | -$56.0M | -$85.8M | -$110.9M | -$121.6M | -$129.5M | -$139.7M |
| Total Equity | $195.3M | $197.4M | -$6.7M | -$6.4M | -$7.9M | -$3.7M | -$322858 | $3.7M | $3.2M |
| Total Debt | 0 | 0 | $2.6M | $4.3M | $17.2M | $4.4M | $854697 | $301660 | $306708 |
| Net Debt | -$2.1M | -$1.7M | $2.3M | $4.1M | $4.9M | $1.3M | -$268907 | -$3.2M | -$4.0M |
| Working Capital | $2.2M | $1.5M | -$6.7M | -$6.7M | -$819073 | -$4.2M | -$1.0M | $3.1M | $2.7M |
Financial Health
| Debt / Equity | -0.25 |
| Current Ratio | 0.70 |
| Piotroski F-Score | 0 |
| Altman Z-Score | -29.36 |
Profitability
| Return on Equity | -316.63% |
| Return on Invested Capital | -320.89% |
| Return on Assets | -136.54% |
| Gross Margin | 100.00% |
| Operating Margin | -1087.47% |
| Net Margin | -1084.23% |
Related companies: AIM · CANF · KALA · KZIA · OGEN · QLGN · SNGX
Explore sector: Healthcare · Biotechnology
More sections of ENSC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks